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Objective: To determine Blastocystis frequency and subtypes (ST) in ulcerative colitis
(UC) patients and analyse some laboratory ﬁndings between Blastocystis positive and
negative cases.
Methods: Faecal samples from 150 UC patients in Adnan Menderes University,
Training and Research Hospital were examined by direct microscopy and cultivated in
Jones medium. Blastocystis positive cultures were subjected to DNA isolation and sub-
types were identiﬁed by sequencing of barcode region. A retrospective analysis was
conducted on C reactive protein (CRP), leucocyte counts (WBC), neutrophil counts, and
sedimentation rates.
Results: The overall positive rate of Blastocystis was 8% (12 patients) and the most
abundant subtype was ST3 (eight isolates, 66.7%), followed by ST1, ST2 and ST7.
Laboratory ﬁndings between Blastocystis infected and non-infected UC patients were not
signiﬁcantly different. Blastocystis frequency was 3.8% among the patients in active
stage, while it was 11.8% among the patients in remission stage.
Conclusions: The present study conﬁrms previous ﬁndings that have indicated the pre-
dominance of Blastocystis ST3 in humans and contributes additional evidence that suggests
the low colonisation ofBlastocystis infection in ulcerative colitis patients during active stage.1. Introduction
Blastocystis is a common intestinal protozoon parasite, found
in humans. Recent researches have shown contradictory ﬁndings
about the pathogenesis of Blastocystis. In a great majority of
human cases, Blastocystis infection is asymptomatic; however,
nonspeciﬁc gastrointestinal and urticarial symptoms may be
observed [1,2]. It was reported that Blastocystis has many
different subtypes (ST) based on its small sub-unit ribosomal
RNA (ssRNA) [3]. These subtypes can be detected by molecular
methods such as sequencing, restriction fragment length
polymorphism or sequence-tagged site-PCR [4]. There have
been many attempts that offered a possible subtype related
pathogenicity, nevertheless much uncertainty still continues
about the relationship [5]. Ulcerative colitis (UC) is a chronic
inﬂammatory disease of large intestine and is increasing in
frequency throughout the world. There has been increasing
evidence that suggests a possible link between gut microbiotaand development of UC either by causing inﬂammation
directly or indirectly through an altered immune system [6,7].
Despite being a common inhabitant of human intestinal tract,
the role of Blastocystis in UC still needs to be investigated.
The primary aim of the present study was to determine
Blastocystis subtypes in UC patients. Additionally, this study
attempted to analyse C reactive protein (CRP), leucocyte counts
(WBC), neutrophil counts, and sedimentation rates between
Blastocystis positive and negative cases.
2. Methods
2.1. Samples
In the present study, faecal samples from 150 UC patients in
Adnan Menderes University, Training and Research Hospital
were collected from June 2013 to the end of February 2015.
2.2. Direct microscopy and culture
Faecal samples were examined by direct microscopy of
native (0.9% serum physiological) and Lugol's iodine prepara-
tions as a part of routine parasitological examination. Anunder the CC BY-NC-ND license (http://
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Jones' medium supplemented with 10% foetal calf serum. The
cultures were checked for the presence of Blastocystis on third
day of inoculation by direct microscopy.
2.3. PCR and sequencing
Prior to DNA isolation the cultures were pelleted by centri-
fugation at 12000 g for one minute. Genomic DNA was isolated
only from positive cultures by using a commercially available kit
DNAzol (Invitrogen) according to manufacturer's instructions. A
single PCR reaction was set with the primers RD5 and BhRDr as
described by Scicluna et al. [4] for ampliﬁcation of ‘barcode
region’, an approximately 600 bp of SSU rRNA gene. The
reaction was set in a 30-mL volume containing: 1–2 mL of
template DNA, 0.4 pmol of each of the primers, 0.3 U of Taq
DNA polymerase (Fermentas), 0.2 mM of each dNTP
(Fermentas), 1 × Taq buffer with (NH4)2SO4 (Fermentas).
PCR amplicons were puriﬁed and sequenced by a commercial
facility (MedSanTek, Istanbul) by using Applied Biosystems
377 DNA Sequencer.
2.4. Determination of subtypes
Subtypes were determined according to closest or exact
match at GenBank nucleotide database using BLAST tool at the
National Center for Biotechnology Information website [8].
Moreover, the sequences were queried against the Blastocystis
Sequence Typing website database (http://pubmlst.org/
Blastocystis/), curated by Stensvold and sited at the University
of Oxford [9].
2.5. Analysis of laboratory ﬁndings
A retrospective analysis was conducted on the following
laboratory ﬁndings: CRP, WBC, neutrophil counts, and sedi-
mentation rates. The patients with endoscopic activity score
below four were considered as in remission stage and the pa-
tients with equal or over four were considered as in active stage
[10]. Data was analysed with non-parametric Mann–Whitney U
test by using Statistical Package for the Social Sciences (SPSS).
3. Results
The overall positive rate of Blastocystis was 8% (12 out of
150) by culture, however the rate was 4.7% (7 out of 150) by
direct microscopy of wet mounts. The most common subtype
was ST3 (eight isolates, 66.7%), followed by ST1 (two isolates,
16.7%), ST2 (one isolate, 8.3%) and ST7 (one isolate, 8.3%).
The sequences were deposited to Genbank with accession
numbers: KU361317–323.
The mean values and standard deviations of laboratory
ﬁndings between Blastocystis infected and non-infected UC
patients were given in Table 1. The mean age of BlastocystisTable 1
Comparison of Blastocystis infected and non-infected UC patients in terms l
Blastocystis n WBC (×103/mL) Neutrophil coun
Positive 11 7626.30 ± 1697.60 4791.80 ±
Negative 112 8404.40 ± 2574.00 5338.30 ±infected and non-infected cases were 54.5 ± 12.0 and
46.5 ± 14.0, respectively. Blastocystis frequency was 3.8% (2
out of 52) among the patients in active stage, while it was
11.8% (8 out of 68) among the patients in remission stage, data
was available for 120 UC patients. The difference was not
signiﬁcantly signiﬁcant (c2 = 2.41, P > 0.05). Moreover, the
infection rate was 7.8% (eight out of the 102) among male and
8.3% (four out of 48) among female patients (c2 = 0.11,
P > 0.05).
4. Discussion
In the present study, ST3 was found as the most common
subtype in UC patients. ST3 is thought as human originated
subtype and reported as predominant in a variety of study
populations. Dogruman-Al et al. [11], found that ST3 was the
most common among IBS, UC and patients with chronic
diarrhoea. Additionally, ST1–3 are the usually reported
subtypes from Turkey. Another subtype from Turkey is avian
ST7 which rarely infects humans [12]. The use of cultures was
suggested in many studies for the detection of Blastocystis
both in epidemiological studies and routine laboratories,
because of the low sensitivity of direct microscopy [13,14]. In
the present study, the rate of positive cases was increased
from 4.7% to 8.0% by the use of Jones medium. However,
Blastocystis frequency could be higher than we detected,
because of the fact that some Blastocystis strains might not
grow in xenic culture [15]. In the present study, the rate of
Blastocystis infection was not related to gender as previously
reported [16].
The role of Blastocystis in certain gastrointestinal diseases
and relations with symptoms are investigated. Nagler et al. [17]
asserted that Blastocystis had no role in Irritable Bowel
Disease (IBD); but the results were based on limited number
of patients (ﬁve UC patients) and unable to encompass the
entire picture. Mumcuoglu et al. [18] reported that the
frequency of Blastocystis was higher among IBS patients and
the symptoms declined after treatment of Blastocystis. In
another study, Blastocystis positive 99 patients were
compared with control group and none of the gastrointestinal
symptoms were found to be related with Blastocystis
infection [19]. It was noted that despite these controversies,
Blastocystis should be screened in UC patients when the
symptoms are refractory [20,21]. Tai et al., [20] interestingly
noted that the elimination of Blastocystis was supportive in
the recovery of gastrointestinal symptoms and also conﬁrmed
their ﬁndings with colonoscopy. In a more recent study,
Krogsgaard et al. [22] compared the frequency of
Dientamoeba fragilis and Blastocystis between asymptomatic
population and IBS patients in Denmark. The authors
reported that the positive rate of Blastocystis was greater in
asymptomatic population than in IBS patients (22% versus
15%) thus indicating that these parasites are not likely to
have a direct role in the pathogenesis of IBS.aboratory ﬁndings.
ts (×103/mL) Sedimentation rates (mm/h) CRP (mg/L)
1065.10 37.18 ± 25.40 13.40 ± 23.60
2241.30 35.10 ± 22.40 18.90 ± 40.60
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tation rates and CRP between Blastocystis infected and non-
infected cases was not signiﬁcantly different in the present
study. CRP is an important marker for the disease activity in UC
patients; in active stage the level is high and in remission it is
usually low [23]. In a previous study, haematological values were
investigated between Blastocystis infected and control group and
CRP and sedimentation rates were found to be signiﬁcantly high
in infected group [24]. Despite being statistically not signiﬁcant,
in our study the rate of Blastocystis was higher in patients who
were in active stage than the patients in remission (11.8% versus
3.8%). This ﬁnding was in accordance with the previous study
[25]. Additionally, Rossen et al. compared patients with active
UC and healthy controls in a cohort, they reported that
Blastocystis was signiﬁcantly less frequent in UC patients
(13.3%) as compared to healthy controls [26]. Nishikawa et al.
compared mucosa-associated microbiota of patients with active
UC and non-IBD controls using terminal restriction fragment
length polymorphism (T-RFLP) analysis; they showed that di-
versity of microbial composition was signiﬁcantly fewer in
active stage [6]. In the present study, data from 120 out of 150
UC patients was available for the activity of diseases. It may
be concluded that this inconsistency may be due to the
number of patients. Furthermore, a study dealing with the
CRP level of Blastocystis infected UC patients in remission
stage would be worthwhile. Our study population was limited
to 150 patients; increasing the number of patients in future
studies would give more brief conclusions.
A limitation of this study is that data has not been supple-
mented with direct PCR of faecal samples which possibly could
increase the positive rate and make comparisons of patient
groups more valid. Additionally, the small number of Blasto-
cystis positive UC patients (12 patients) prevented making
parametric statistics between groups. Roberts et al. compared
different methods and found PCR as the most sensitive at
detecting Blastocystis [27]. Additionally, in another study, the
positive rate of Blastocystis was 41.0% by culture and it was
44.6% by PCR [28].
In conclusion, the present study conﬁrms previous ﬁndings
that indicate the predominance of Blastocystis ST3 in humans
and provides additional evidence that suggests low colonisa-
tion of Blastocystis infection in UC patients during active
stage. Additionally, further studies investigating some other
laboratory ﬁndings in Blastocystis infected UC patients will be
worthwhile.
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